76results about "Polypeptide with affinity tag" patented technology

Provided is a method for producing a heterodimeric protein such as a bispecific antibody with which a heterodimeric protein composed of only domains having natural amino acid sequences can also be produced. A production method of the present invention is a method for producing a heterodimeric protein. The production method includes a production step of producing a heterodimeric protein by reacting a dimeric protein having a reaction tag with a modification protein for modifying the dimeric protein. The dimeric protein having a reaction tag includes a first monomeric protein and a second monomeric protein. The first monomeric protein includes a first reaction tag and a first dimer formation domain capable of forming a dimer in this order. The first reaction tag includes a binding tag and a first C intein. The second monomeric protein includes a second reaction tag and a second dimer formation domain capable of forming a dimer together with the first dimer formation domain in this order. The second reaction tag includes a binding partner capable of binding to the binding tag, and a second C intein. The modification protein includes a first modification protein and a second modification protein. The first modification protein includes a first N intein capable of reacting with the first C intein, and a first addition component to be added to the first monomeric protein. The second modification protein includes a second N intein capable of reacting with the second C intein, and a second addition component to be added to the second monomeric protein. The first addition component and the second addition component are different addition components. The first monomeric protein and the second monomeric protein form a dimer. In the production step, the first N intein of the first modification protein reacts with the first C intein of the first monomeric protein, and then the first addition component of the first modification protein is linked to the first monomeric protein, and the second N intein of the second modification protein reacts with the second C intein of the second monomeric protein, and then the second addition component of the second modification protein is linked to the second monomeric protein.

The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.

The present application relates to the field of biological medicine and clinical diagnosis, and more particularly, the present application relates to a polypeptide having binding affinity to AXL protein and application thereof; the polypeptide has binding affinity to AXL protein, and therefore can be used for detecting AXL protein, so that the polypeptide has diagnostic or therapeutic use as a drug or molecular targeting reagent.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

In alternative embodiments, provided are synthetic, or non-natural, protein heterodimers or homodimers whose protein / protein binding interactions are controlled through metal or small molecule binding, and methods of making and using them. In alternative embodiments, provided are metal-controlled or small molecule-controlled heterodimers or homodimers, wherein each dimer is fused or joined to half or a portion of a detectable entity, and the when the two dimers are joined or come in contact with each other because of each dimer's binding to a metal, the detectable entity's halves, now also joined or having come in contact with each other, only now can directly or indirectly generate or initiate a detectable signal. In alternative embodiments, provided are biosensors or microfluidic devices comprising synthetic, or non-natural, protein heterodimers or homodimers as provided herein.

The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and / or protein mixtures.

The invention provided herein relates to methods for cell-free protein synthesis and characterisation. Provided is an automated system for analysing expression and purification of proteins.

The disclosure, in some aspects, provides antigen-specific amino acid sequences for tick-borne relapsing fever Borrelia species.

The present disclosure relates to novel cell wall binding domains, enzymatically active domains, and chimeric cell wall hydrolases with anti-Cutibacterium acnes activity. The disclosure also relates to compositions comprising these, and uses thereof in the treatment of conditions associated with Cutibacterium acnes.

Provided are archaeal Cas9 polypeptides and nucleic acids encoding same, which are RNA-guided endonuclease polypeptides useful in Class 2 CRISPR / Cas systems (e.g., Cas protein + guide RNA combinations), as well as their associated guide RNAs (archaeal Cas9 guide RNAs) and nucleic acids encoding same, and modified host cells containing the nucleic acids. The present invention provides compositions comprising a CasX polypeptide and / or a nucleic acid encoding a CasX polypeptide.

This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.

The present invention is directed to a peptide, wherein said peptide has an amino acid sequence according to SEQ ID NO. 1. The present invention also discloses compositions comprising said peptide and specific uses.

Technologies for the prevention and / or treatment of Salmonella infections.

The present invention relates to a novel chimeric adapter protein and an extracellular vesicle containing the same, and more particularly, to a novel chimeric adapter protein and an extracellular vesicle containing the same, according to one aspect, the chimeric adapter protein can be abundantly expressed on the surface of the extracellular vesicle, has excellent binding efficiency, and does not interact with other components on the surface of the extracellular vesicle, thereby maintaining the integrity of the extracellular vesicle, etc. Good bioavailability and modularization are realized. When the medicine is loaded in the extracellular vesicles, the extracellular vesicles can also be used as an effective nano-carrier.

The invention relates to the use of precursor peptides and B1 proteins from lasso peptide biosynthesis systems for affinity purification, proximity-based sortase-mediated protein purification and ligation, and detection of fusion proteins. For proximity-based sortase-mediated protein purification and ligation, the invention relates to techniques that link protein purification with conjugation to other agents, including therapeutic agents, imaging agents, or linkers.

The object of the present invention is to provide novel means that can be used for solubilizing proteins with poor water solubility. Provided is a hydrophilic solubilizing group for proteins or peptides, comprising a sugar chain moiety; and a functional group moiety that is bound to the amino or carboxy group of said sugar chain, and that binds to the amino acid side chain and can be detached from said protein or amino acid side chain in the presence of an acid.

Disclosed are a fusion protein and an immobilized enzyme including the fusion protein, where the fusion protein includes an epoxide hydrolase active domain and a chitin protein binding domain. The present disclosure achieves efficient immobilization of epoxide hydrolase through the specific affinity between chitin and the fusion protein, and uses ethylhexyl glycidyl ether as a substrate to efficiently produce ethylhexylglycerin with the immobilized enzyme. The immobilization method of the present disclosure offers advantages such as low cost, high enzyme immobilization efficiency, minimal enzyme activity loss, and strong specificity, fundamentally solving issues like poor recyclability and low stability of free enzymes, as well as low repeatability in traditional whole-cell immobilization methods. It resolves issues such as deep color and protein residues in downstream separation and purification.

Compositions, methods, and kits for performing multiplexed, spatially resolved, or single-cell chromatin analysis are provided.

The present disclosure relates to novel cell wall binding domains, enzymatically active domains, and chimeric cell wall hydrolases with anti-Cutibacterium acnes activity. The disclosure also relates to compositions comprising these, and uses thereof in the treatment of conditions associated with Cutibacterium acnes.

Hypersensitive response eliciting peptides exhibiting improved solubility, stability, resistance to chemical degradation, or a combination of these properties are disclosed. Also disclosed are uses of these peptides or fusion polypeptides or DNA constructs encoding the same for modulating plant biochemical signaling, conferring disease resistance to a plant, enhancing plant growth, conferring tolerance to a plant to a biotic stress, conferring tolerance and resistance to a plant to an abiotic stress, conferring desiccation resistance to a cutting taken from an ornamental plant, conferring postharvest disease resistance or postharvest desiccation resistance to a fruit or vegetable, or enhancing the postharvest life of a fruit or vegetable.

Provided is a heterodimeric protein production method for heterodimeric proteins such as bispecific antibodies, by which it is possible to produce a heterodimeric protein composed solely of domains comprising natural amino acid sequences.　This production method is a heterodimeric protein production method comprising a production step in which a dimeric protein including a reaction tag is reacted with a modifying protein for modifying the dimeric protein, to produce a heterodimeric protein. The dimeric protein including the reaction tag comprises a first monomeric protein and a second monomeric protein; the first monomeric protein comprises, in the following order, a first reaction tag and a first dimer formation domain capable of forming a dimer; the first reaction tag comprises a binding tag and a first C-intein; the second monomeric protein comprises, in the following order, a second reaction tag, the first dimer formation domain, and a second dimer formation domain capable of forming a dimer; the second reaction tag comprises a binding partner capable of binding to the binding tag, and a second C-intein; the modifying protein comprises a first modifying protein and a second modifying protein; the first modifying protein comprises a first N-intein capable of reacting with the first C-intein, and a first adduct added to the first monomeric protein; the second modifying protein comprises a second N-intein capable of reacting with the second C-intein, and a second adduct added to the second monomeric protein; the first adduct and the second adduct are different adducts; the first monomeric protein and the second monomeric protein form a dimer; and in the production step, the first N-intein of the first modifying protein reacts with the first C-intein of the first monomeric protein, the first adduct of the first modifying protein is joined to the first monomeric protein, the second N-intein of the second modifying protein reacts with the second C-intein of the second monomeric protein, and the second adduct of the second modifying protein is joined to the second monomeric protein.

This disclosure concerns production of product peptides with a target amino acid sequence by proteolysis of a recombinant polypeptide comprising specific protease recognition sites or chemical cleavage sequences. In some embodiments, the product peptide is released from repeating peptide units in the recombinant polypeptide by removal of intervening amino acid sequences by proteolysis by proteases that recognize sites within the intervening amino acid sequences and a carboxypeptidase, aminopeptidase, and / or further protease.

To provide a drug delivery platform for cell therapy that can control cell activity after transplantation in order to avoid concerns such as tumorigenesis of transplanted cells, in treatment or regenerative medical treatment using chimeric antigen receptor T cells and stem cells.SOLUTION: Provided is a drug delivery platform for cell therapy, comprising: a. an engineered protein on a target cell for transplant consisting of a fusion protein with a first component and a second component, the first component and the second component being bound by a peptide linker, the first component being a non-membrane protein, the second component being a membrane anchored peptide or protein; b. at least one small ligand bound to a linker, and having intrinsic high affinity to at least one component of the engineered protein; and c. at least one payload of drug bound to the linker, and associated with the target cell when the small ligand binds to at least one component of the engineered protein.SELECTED DRAWING: None

The present invention relates to genetically encoded cellular iron biosensors, in particular to nucleic acids encoding the same, vectors and cells comprising the nucleic acid(s), in vitro methods for measuring, and optionally monitoring, cellular Fe2+ and / or cellular iron-sulfur cluster (ISC), in vitro screening methods for a compound that affects cellular Fe2+ and / or cellular ISC, and to in vitro methods for identifying a dosage and / or formulation of a compound that affects cellular Fe2+ and / or cellular ISC.

A variant polypeptide of fructanase, a fusion protein and an enzyme composition comprising said variant polypeptide, recombinant host cell producing the variant polypeptide, method for manufacturing the variant polypeptide, a use of the variant polypeptide to degrade and modify fructan containing material, and a premix for baking comprising the variant polypeptide.

Disclosed herein are compositions, methods, and systems for the purification and / or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

Disclosed are blocking peptides and related methods, formulations, and compositions, pertaining to the field of biomedicine. Based on the regulatory mechanism by which the negative regulator TGF-β modulates the transport and degradation of STING, the use of AP3D1 as a drug target for in vitro screening of blocking agents is provided to identify the S9 regulatory site and the R26 regulatory site of AP3D1. Corresponding blocking peptides targeting the S9 regulatory site and the R26 regulatory site, respectively, were synthesized to specifically inhibit AP3D1-mediated inactivation of STING signaling by tumor microenvironment factors, thereby blocking at least one of the S9 regulatory site and the R26 regulatory site and effectively restricting STING transport and degradation. The blocking peptide can synergize with various treatment modalities, including chemotherapy, radiotherapy, PARP inhibitors, and STING agonists, significantly enhancing cGAS-STING signaling activation in tumors during therapy and achieving more potent antitumor efficacy.

The present disclosure relates to an orthogonal system comprising a first bispecific polypeptide comprising D-streptavidin or a variant thereof covalently bound to an antibody or antibody fragment, and a conjugate comprising L-biotin covalently bound to a therapeutic or diagnostic agent. The system of the present disclosure can be useful, for example, in the treatment of a disease or condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Peptides and polypeptides useful in the preparation of the disclosed bispecific polypeptides, and methods of making them, are also described. This summary is intended as a scanning tool for purposes of searching in a particular art and is not intended to limit the present invention.